tirzepatide compound fda GLP-1 compounding is still in limbo. Will the leave it for the next administration? May 18, 2026: FDA warns

Mold illness: Mold toxins deplete glutathione

10.1164/rccm.201305-0908LE Am J Respir Crit Care Med

By OAC Staff Summer 2026 At the Obesity Action Coalition (OAC), we have long advocated for a better understanding of obesity as a chronic disease and for increased access to science-based obesity treatments

For example, different actions of GLP-1 receptor agonists such as delaying gastric emptying which leads to a prolonged feeling of fullness and reducing food intake lead to significant weight loss ( Endogenous GLP-1 has a short half-life since it is in 1-2 minutes degraded by the enzyme dipeptidyl peptidase-4 (DPP-4)